SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Jaguar Health, Inc.
Date: June 25, 2025 · CIK: 0001585608 · Accession: 0000000000-25-006641

Offering / Registration Process Regulatory Compliance

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288202

Date
June 25, 2025
Author
Division of
Form
UPLOAD
Company
Jaguar Health, Inc.

Letter

Re: Jaguar Health, Inc. Registration Statement on Form S-3 Filed June 20, 2025 File No. 333-288202 Dear Lisa Conte:

June 25, 2025

Lisa Conte Chief Executive Officer Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Michael S. Lee, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 June 25, 2025

Lisa Conte
Chief Executive Officer
Jaguar Health, Inc.
200 Pine Street, Suite 400
San Francisco, CA 94104

 Re: Jaguar Health, Inc.
 Registration Statement on Form S-3
 Filed June 20, 2025
 File No. 333-288202
Dear Lisa Conte:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tyler Howes at 202-551-3370 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Michael S. Lee, Esq.
</TEXT>
</DOCUMENT>